Skip to Content

Peramivir Pregnancy and Breastfeeding Warnings

Peramivir is also known as: Rapivab

Medically reviewed on May 30, 2018

Peramivir Pregnancy Warnings

Benefit should outweigh risk.

US FDA pregnancy category: Not assigned.

Risk summary: Insufficient data available on use of this drug in pregnant women to inform a drug-related risk.

Comments:
-Risks to mother and fetus associated with influenza during pregnancy should be considered.

Animal studies have revealed evidence of fetal abnormalities (reduced renal papilla, dilated ureters) when administered by continuous IV infusion but failed to reveal evidence of fetotoxicity when administered by IV bolus injection in rats; developmental toxicity (abortion/premature delivery) was shown at maternally toxic doses in rabbits. Animal studies have shown that this drug crosses the placenta. There are no controlled data in human pregnancy.

Pregnant women have higher risk of severe complications from influenza, which may lead to adverse pregnancy and/or fetal outcomes.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Peramivir Breastfeeding Warnings

If the mother requires this drug, it is not a reason to discontinue breastfeeding; however, an alternative agent may be preferred, particularly while breastfeeding newborn or preterm infants.
-Safety has not been established.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

Comments:
-No data available on use of this drug during breastfeeding; this drug is not likely to reach the infant's bloodstream in clinically significant amounts since it is poorly absorbed orally.
-Developmental and health benefits of breastfeeding should be considered as well as the mother's clinical need for this drug.
-The effects in the nursing infant are unknown; potential side effects in the breastfed child due to this drug or the mother's underlying condition should be considered.

See references

References for pregnancy information

  1. "Product Information. Rapivab (peramivir)." BioCryst Pharmaceuticals Inc, Durham, NC.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  2. "Product Information. Rapivab (peramivir)." BioCryst Pharmaceuticals Inc, Durham, NC.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide